Overview

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C

Status:
Enrolling by invitation

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this extension study is to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study will be a global multicenter study.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis Pharmaceuticals
The Medicines Company